JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 90 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5,000 | -64.3% | 4,882 | -18.5% | 0.00% | – |
| Q3 2022 | $14,000 | -75.9% | 5,990 | -68.5% | 0.00% | – |
| Q2 2022 | $58,000 | -40.2% | 18,990 | +32.8% | 0.00% | – |
| Q1 2022 | $97,000 | -18.5% | 14,303 | 0.0% | 0.00% | – |
| Q4 2021 | $119,000 | +138.0% | 14,303 | +101.8% | 0.00% | – |
| Q4 2020 | $50,000 | -13.8% | 7,088 | 0.0% | 0.00% | – |
| Q3 2020 | $58,000 | +18.4% | 7,088 | 0.0% | 0.00% | – |
| Q2 2020 | $49,000 | +44.1% | 7,088 | 0.0% | 0.00% | – |
| Q1 2020 | $34,000 | -8.1% | 7,088 | +68.8% | 0.00% | – |
| Q4 2019 | $37,000 | +164.3% | 4,200 | 0.0% | 0.00% | – |
| Q3 2019 | $14,000 | – | 4,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pharmstandard International S.A. | 662,063 | $10,315,000 | 30.07% |
| Omega Fund Management, LLC | 579,650 | $9,031,000 | 5.11% |
| Casdin Capital, LLC | 399,825 | $6,229,000 | 1.76% |
| Cormorant Asset Management, LP | 359,738 | $5,605,000 | 0.99% |
| Foresite Capital Management II, LLC | 119,912 | $1,868,000 | 0.76% |
| Redmile Group, LLC | 955,598 | $14,888,000 | 0.73% |
| PFM Health Sciences, LP | 1,727,997 | $26,922,000 | 0.53% |
| Fosun International Ltd | 285,960 | $4,455,000 | 0.44% |
| Partner Investment Management, L.P. | 14,265 | $222,000 | 0.21% |
| Spark Investment Management LLC | 162,200 | $2,527,000 | 0.14% |